<DOC>
	<DOCNO>NCT01783678</DOCNO>
	<brief_summary>This Open-label Phase 3 study adult chronic genotype 1 , 2 , 3 , 4 HCV infection co-infected HIV-1 .</brief_summary>
	<brief_title>A Phase 3 , Open-label Study Investigate Efficacy Safety Sofosbuvir Plus Ribavirin Chronic Genotype 1 , 2 , 3 4 Hepatitis C Virus ( HCV ) Human Immunodeficiency Virus ( HIV ) Co-infected Adults</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Age ≥ 18 year HIV1 chronic HCV genotype 1 , 2 , 3 , 4 coinfection HCV RNA &gt; 10,000 IU/mL screen HCV treatment history : Treatmentnaive HCV genotypes 1 , 2 , 3 , 4 , Treatmentexperienced HCV genotypes 2 3 HIV antiretroviral ( ARV ) criterion : On stable , protocolapproved , HIV ARV regimen undetectable HIV RNA &gt; 8 week prior screen , ARV untreated ≥ 8 week prior screen , CD4 Tcell count &gt; 500 cells/mm^3 Presence absence cirrhosis ; liver biopsy may require Healthy accord medical history physical examination exception HCV HIV diagnosis Agree use two form highly effective contraception duration study 6 month last dose study medication HCV genotype 1 4 previous HCV treatment Poor control HIV ARV regimen require possible dose modification therapy within 4 week study medication dose A new AIDSdefining condition diagnose within 30 day prior screen Prior use inhibitor HCV NS5B polymerase History clinically significant chronic liver disease Evidence history decompensated liver disease Chronic hepatitis B virus ( HBV ) infection Hepatocellular carcinoma ( HCC ) malignancy ( exception certain resolve skin cancer ) Chronic use immunosuppressive agent immunomodulatory agent Clinically relevant drug alcohol abuse within 12 month screen History current evidence condition , therapy , laboratory abnormality circumstance might confound result study , interfere participant 's participation full duration study best interest participant opinion investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>